Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study
Arvind N. Dasari, Sara Lonardi, Rocio García‐Carbonero et al. · The Lancet · 2023
Cited by 353 works. doi:10.1016/s0140-6736(23)00772-9
Authors
- Arvind N. Dasari
- Sara Lonardi
- Rocio García‐Carbonero
- Elena Élez
- Takayuki Yoshino
- Alberto Felice Sobrero
- James C. Yao
- Pilar García Alfonso
- Judit Kocsis
- Antonio Cubillo Gracián
- Andrea Sartore Bianchi
- Taroh Satoh
- Violaine Randrian
- Jiří Tomášek
- Geoff Chong
- Andrew Scott Paulson
- Toshiki Masuishi
- Jeremy Clifton Jones
- Tibor Csőszi
- Chiara Cremolini
References
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
- VEGF-targeted therapy: mechanisms of anti-tumour activity
- Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
- Comprehensive review of targeted therapy for colorectal cancer
- Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer
- Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy
- VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects